Invivyd, Inc.
NASDAQ:IVVDBiotechnology
+$0.04 today
- Market cap
- $138.68M
- Beta
- 0.63
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$0.25
Volume 6.71M
Average 3.62M
IVVD Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Invivyd, Inc.NASDAQ: IVVD
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital declines year over year
Q1 FY2026 change in working capital of $3.58M (cash outflow) fell 57.4% year over year, behind the -22.8% change in trailing-twelve-month change in working capital. Sequentially, it fell 51.6% from the prior quarter. Over 3 fiscal years it compounded at +6.9% a year.
Context
- Change in working capital amounted to 36.9% of revenue in FY2025, down 55.6 pp from a year earlier.
- Change in working capital increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -57.4% toward the trailing-twelve-month pace of -22.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- (19.69M) USD
- Year-over-year change
- +16.1%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (19.69M) | +16.1% |
| FY2024 | 2024-12-31 | (23.47M) | -498.6% |
| FY2023 | 2023-12-31 | 5.89M | +136.5% |
| FY2022 | 2022-12-31 | (16.13M) | -170.8% |
| FY2021 | 2021-12-31 | 22.79M | — |
Change in Working Capital vs competitors
How IVVD compares with its peers on the latest reported figures
- IVVD's LTM Mar 2026 change in working capital of $14.87M is the 2nd largest of the 10 companies compared; the peer median is $4.58M.
- Its year-over-year change of -22.8% is the 5th highest of 9, against a peer median of +60.8%.
- Change in working capital amounts to 26.6% of revenue for IVVD, versus a peer median of 32.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $23.74M | +149.1% | +20.4% | 68.1% | |
| LTM Mar 2026 | $14.87M | -22.8% | +6.9% | 26.6% | |
| LTM Mar 2026 | $13.05M | +2413.5% | +184.4% | 39.9% | |
| LTM Mar 2026 | $8.1M | — | — | — | |
| LTM Mar 2026 | $7.29M | -27.6% | -23.0% | 25.2% | |
| LTM Mar 2026 | $5.7M | -57.2% | -62.8% | 16.5% | |
| LTM Mar 2026 | $4.58M | -40.8% | -33.2% | 5.9% | |
| LTM Mar 2026 | $4.24M | -538.4% | — | — | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $3.89M | +220.7% | — | 199.6% |
| LTM Sep 2026 | $3.66M | +151.2% | — | — | |
| Peer median (excluding IVVD) | $4.58M | +60.8% | -23.0% | 32.5% | |
Competitors are the stored peer set for IVVD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (226.79M) | (241.32M) | (198.64M) | (169.93M) | (52.49M) |
| Depreciation & Amortization | 1K | 462K | 2.03M | 3.11M | 2.11M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 17.76M | 21.65M | 18.69M | 19.79M | 11.64M |
| Change in Working Capital | 22.79M | (16.13M) | 5.89M | (23.47M) | (19.69M) |
| Accounts Receivables | 0 | 0 | 0 | (10.91M) | (3.34M) |
| Inventory | 0 | 0 | 0 | (24.89M) | (373K) |
| Accounts Payables | (2.37M) | (4.3M) | 6.47M | 2.42M | 3.21M |
| Other Working Capital | 25.16M | (11.83M) | (583K) | 9.91M | (19.2M) |
| Other Non-Cash Items | 1.5M | 15.35M | (1.12M) | 19.79M | 298K |
| Operating Cash Flow | (184.74M) | (219.99M) | (173.16M) | (170.49M) | (58.14M) |
| Capital Expenditures | (84K) | (1.71M) | (615K) | (140K) | (155K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (188.63M) | (297.96M) | (91.2M) | 0 | 0 |
| Sales of Investments | 138M | 69M | 372.5M | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (50.71M) | (230.67M) | 280.68M | (140K) | (155K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 330.91M | 510K | 1.2M | 39.29M | 215.63M |
| Common Stock Repurchased | 0 | (4K) | (1K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.39M) | 510K | 1.05M | 46K | 0 |
| Financing Cash Flow | 662.68M | 506K | 1.05M | 39.33M | 215.63M |
| Effect of Forex Changes | 0 | 0 | 0 | 8K | 0 |
| Net Change in Cash | 427.24M | (450.15M) | 108.57M | (131.29M) | 157.34M |
| Free Cash Flow | (184.82M) | (221.69M) | (173.78M) | (170.63M) | (58.29M) |
Invivyd, Inc.
NASDAQ:IVVD
Intrinsic Alpha fair value
Locked
Current Price
$0.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.